Cytrellis Biosystems
Woburn, US · Founded 2011 · Delaware corporation · 1 known investors
Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.
Founders & leadership
RA
Rox Anderson, MDFounder, Medical / Technology Advisor
WG
William G. Austen, Jr. MDFounder, Medical / Technology Advisor
DL
Doug Levinson, PhDFounder
DD
Denise Dajles, PhDPresident & CEO
JM
John McDonoughExecutive Officer, Director
KC
Keith CrandallDirector
DS
David StoneExecutive Officer
DC
David CruikshankDirector
AM
Amit MunshiDirector
DA
Douglas A. LevinsonExecutive Officer, Director
KL
Keith L. CrandellDirector
FA
Fred Aslan, MDDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$25.1MraisedDec 2024 · 15 investors · Other Health CareRule 506(b)
▶$25.1MraisedDec 2024 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Keith L. CrandellDirector
- Fred Aslan, MDDirector
- Frederick Beddingfield III, MDDirector
- Michael PetersonDirector
- John McDonoughExecutive Officer, Director
- Offering amount
- $32.1M
- Amount sold
- $25.1M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedJan 2021 · 14 investors · Other Health CareRule 506(b)
▶$50MraisedJan 2021 · 14 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL PETERSONDirector
- FREDERICK BEDDINGFIELD III, MDDirector
- KEITH L. CRANDELLDirector
- JOHN MCDONOUGHDirector
- DIANE MARCOUExecutive Officer
- KAREN CRONHOLMExecutive Officer, Director
- FRED ASLAN, MDDirector
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.1MraisedFeb 2015 · 21 investors · Other Health CareRule 506(b)
▶$7.1MraisedFeb 2015 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- John McDonoughDirector
- Keith CrandallDirector
- David StoneExecutive Officer
- David CruikshankDirector
- Amit MunshiDirector
- Douglas A. LevinsonExecutive Officer, Director
- Offering amount
- $13.9M
- Amount sold
- $7.1M
- First sale
- Feb 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Cytrellis Biosystems launches Updated Next-Generation Skin Removal Treatment ellacor® 2.0, fueled by new leadership and financingglobenewswire.com · 2025
- Cytrellis Biosystems 9/22/2021 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com · 2021
- Cytrellis Biosystems Completes $50 Million Series C Financingprnewswire.com · 2021
- Cytrellis Biosystems Raises $28.5M in Series B Financing - FinSMEsfinsmes.com · 2018
- Merz Venture Initiative Increases Investment in Cytrellis - Merz Pharmareinheim.merz.com